Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behçet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation

[1] Evereklioglu C(2005)Current concepts in the etiology and treatment of Behçet disease Surv Ophthalmol 50 297-350

[2] Evereklioglu C(2004)Managing the symptoms of Behçet’s disease Expert Opin Pharmacother 5 317-328

[3] Evereklioglu C(2002)Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease Mediat Inflamm 11 87-93

[4] Er H(2008)Sustained remission after infliximab in a child with systemic vasculitis refractory to conventional immunosuppressive therapy including interferon-α Br J Ophthalmol 92 1034-516

[5] Türköz Y(2011)Ocular Behçet disease: current therapeutic approaches Curr Opin Ophthalmol 22 508-516

[6] Çekmen M(2005)Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop Am J Ophthalmol 140 509-471

[7] Evereklioglu C(1985)Standardization of vitreal inflammatory activity in intermediate and posterior uveitis Ophthalmology 924 467-82

[8] Borlu M(2023)Twenty years of quiescence after nonstop Remicade Case Rep Ophthalmol 14 75-2089

[9] Evereklioglu C(2019) (Infliximab) infusions in a child with ocular Behçet disease presenting as hypopyon-anterior uveitis refractory to immunosuppressants Arthritis Rheumatol 71 2081-1581

[10] Jabs DA(2012)Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease: national multicenter study of 177 cases Ophthalmology 119 1575-2231

[1] Evereklioglu C(2005)Current concepts in the etiology and treatment of Behçet disease Surv Ophthalmol 50 297-350

[2] Evereklioglu C(2004)Managing the symptoms of Behçet’s disease Expert Opin Pharmacother 5 317-328

[3] Evereklioglu C(2002)Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease Mediat Inflamm 11 87-93

[4] Er H(2008)Sustained remission after infliximab in a child with systemic vasculitis refractory to conventional immunosuppressive therapy including interferon-α Br J Ophthalmol 92 1034-516

[5] Türköz Y(2011)Ocular Behçet disease: current therapeutic approaches Curr Opin Ophthalmol 22 508-516

[6] Çekmen M(2005)Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop Am J Ophthalmol 140 509-471

[7] Evereklioglu C(1985)Standardization of vitreal inflammatory activity in intermediate and posterior uveitis Ophthalmology 924 467-82

[8] Borlu M(2023)Twenty years of quiescence after nonstop Remicade Case Rep Ophthalmol 14 75-2089

[9] Evereklioglu C(2019) (Infliximab) infusions in a child with ocular Behçet disease presenting as hypopyon-anterior uveitis refractory to immunosuppressants Arthritis Rheumatol 71 2081-1581

[10] Jabs DA(2012)Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease: national multicenter study of 177 cases Ophthalmology 119 1575-2231